Loading
Selta Square
Selta Square sells AI and RPA-based pharmacovigilance tools. They cover literature search (LITUS), safety-data entry and review (WAVE), and MedDRA coding (SELTA-OCTO). It also runs Oracle Argus-based case processing and regulatory reporting as an outsourced service (PVaaS, launched July 2022). Customers include Korean drugmakers such as Yuhan, Hanmi and Daewoong, and the company was launched with Daewoong Pharmaceutical's help in 2020. It raised a reported $6.3M Series A in January 2025 and has roughly 16–18 employees.
Funding
Every round, secondary, debt facility or acquisition involving Selta Square that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—